In several cancer cells overexpressing ErbB2, inhibition of ErbB2 alone by specific inhibitors seems to be impossible since it is well known that ErbB2 is the preferential partners of the ErbB receptors, including EGFR [31]. The gene discussed is EGFR; the disease is cancer.